CARDIO DIAGNOSTICS HOLDINGS
CDIONASDAQ🏆 #4634 by market capEarnings Dec 2US Equity
$2.00▲ $0.19 (+9.29%)
Live1h▲ 2.6%
24h▲ 9.3%
7d▲ 13.6%
14d▲ 26.6%
30d▲ 10.5%
1y▼ 44.8%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
-57.5%
Declining
📊Gross Margin
-555.0%
Thin
💵FCF Margin
-40425.3%
Thin
⚖️P/S Ratio
409.6x
Expensive
Otter Score
46
Weak
Trading Snapshot
- Day Range
- $1.99 – $2.01
- 52-Week Range
- $0.97 – $7.91
- Volume
- $2.67B
- Avg Volume
- $2.75B
- Shares Outstanding
- 3.0M
- Next Earnings
- Sep 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $14,825
- Last Q Revenue
- $5,360
- P/E Ratio
- -0.7
- P/S Ratio
- 409.6x
- EPS (TTM)
- $-2.19
- Dividend Yield
- 0.00%
Why Investors Own CDIO
- ✓High-growth profile — revenue up +52.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$14,825▲ +53.8% YoY
Gross Margin (TTM)
43.0%▲ +0.7% YoY
Operating Income (TTM)
$2,090▲ +53.8% YoY
Free Cash Flow (TTM)
$3,677▲ +53.8% YoY
About CARDIO DIAGNOSTICS HOLDINGS
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2025
